Author Correction: The state of the art in secondary pharmacology and its impact on the safety of new medicines

Richard J Brennan^#¹, Stephen Jenkinson^#^{2

3}, Andrew Brown⁴, Annie Delaunois⁵, Bérengère Dumotier⁶, Malar Pannirselvam^{7

8}, Mohan Rao^{9

10}, Lyn Rosenbrier Ribeiro^{5

11

12}, Friedemann Schmidt¹³, Alicia Sibony⁵, Yoav Timsit^{14

15}, Vicencia Toledo Sales¹⁶, Duncan Armstrong^{14

17}, Armando Lagrutta¹⁸, Scott W Mittlestadt¹⁹, Russell Naven^{16

14}, Ravikumar Peri^{16

20}, Sonia Roberts²¹, James M Vergis²², Jean-Pierre Valentin^#⁵

Affiliations

¹ Sanofi, Cambridge, MA, USA. richbrennan@gmail.com.
² Pfizer, La Jolla, CA, USA.
³ Metrion Biosciences, San Diego, CA, USA.
⁴ GSK, Stevenage, UK.
⁵ UCB Biopharma, Braine-l'Alleud, Belgium.
⁶ Novartis Biomedical Research, Basel, Switzerland.
⁷ Vertex Pharmaceuticals, Boston, MA, USA.
⁸ GSK, Waltham, MA, USA.
⁹ Janssen Research & Development, San Diego, CA, USA.
¹⁰ Neurocrine Biosciences, San Diego, CA, USA.
¹¹ AstraZeneca, Cambridge, UK.
¹² Grunenthal, Berkshire, UK.
¹³ Sanofi, Frankfurt, Germany.
¹⁴ Novartis Biomedical Research, Cambridge, MA, USA.
¹⁵ Blueprint Medicines, Cambridge, MA, USA.
¹⁶ Takeda Pharmaceuticals, Cambridge, MA, USA.
¹⁷ Armstrong Pharmacology, Macclesfield, UK.
¹⁸ Merck, North Wales, PA, USA.
¹⁹ AbbVie, North Chicago, IL, USA.
²⁰ Alexion Pharmaceuticals, Wilmington, DE, USA.
²¹ Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.
²² Faegre Drinker Biddle and Reath, LLP, Washington, DC, USA.

^# Contributed equally.

Published Erratum

Richard J Brennan et al. Nat Rev Drug Discov. 2024 Jul.

. 2024 Jul;23(7):563.

doi: 10.1038/s41573-024-00993-6.

¹ Sanofi, Cambridge, MA, USA. richbrennan@gmail.com.
² Pfizer, La Jolla, CA, USA.
³ Metrion Biosciences, San Diego, CA, USA.
⁴ GSK, Stevenage, UK.
⁵ UCB Biopharma, Braine-l'Alleud, Belgium.
⁶ Novartis Biomedical Research, Basel, Switzerland.
⁷ Vertex Pharmaceuticals, Boston, MA, USA.
⁸ GSK, Waltham, MA, USA.
⁹ Janssen Research & Development, San Diego, CA, USA.
¹⁰ Neurocrine Biosciences, San Diego, CA, USA.
¹¹ AstraZeneca, Cambridge, UK.
¹² Grunenthal, Berkshire, UK.
¹³ Sanofi, Frankfurt, Germany.
¹⁴ Novartis Biomedical Research, Cambridge, MA, USA.
¹⁵ Blueprint Medicines, Cambridge, MA, USA.
¹⁶ Takeda Pharmaceuticals, Cambridge, MA, USA.
¹⁷ Armstrong Pharmacology, Macclesfield, UK.
¹⁸ Merck, North Wales, PA, USA.
¹⁹ AbbVie, North Chicago, IL, USA.
²⁰ Alexion Pharmaceuticals, Wilmington, DE, USA.
²¹ Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.
²² Faegre Drinker Biddle and Reath, LLP, Washington, DC, USA.

^# Contributed equally.

No abstract available

Erratum for

The state of the art in secondary pharmacology and its impact on the safety of new medicines.
Brennan RJ, Jenkinson S, Brown A, Delaunois A, Dumotier B, Pannirselvam M, Rao M, Ribeiro LR, Schmidt F, Sibony A, Timsit Y, Sales VT, Armstrong D, Lagrutta A, Mittlestadt SW, Naven R, Peri R, Roberts S, Vergis JM, Valentin JP. Brennan RJ, et al. Nat Rev Drug Discov. 2024 Jul;23(7):525-545. doi: 10.1038/s41573-024-00942-3. Epub 2024 May 21. Nat Rev Drug Discov. 2024. PMID: 38773351 Review.